Evidence map›Paper›PMID 33931709›Full record

Trial reportScientific reports2021

Histamine receptor 2 blockade selectively impacts B and T cells in healthy subjects.

Dihia Meghnem, Sharon A Oldford, Ian D Haidl, Lisa Barrett, Jean S Marshall

Open access · goldAbstract readClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Dihia MeghnemDalhousie Human Immunology and Inflammation Group, Department of Microbiology and Immunology, Dalhousie University, Sir Charles Tupper Medical Building, Room 7-C2, 5850 College Street, PO Box 15000, Halifax, NS, B3H 4R2, Canada.
Sharon A OldfordDalhousie Human Immunology and Inflammation Group, Department of Microbiology and Immunology, Dalhousie University, Sir Charles Tupper Medical Building, Room 7-C2, 5850 College Street, PO Box 15000, Halifax, NS, B3H 4R2, Canada.
Ian D HaidlDalhousie Human Immunology and Inflammation Group, Department of Microbiology and Immunology, Dalhousie University, Sir Charles Tupper Medical Building, Room 7-C2, 5850 College Street, PO Box 15000, Halifax, NS, B3H 4R2, Canada.
Lisa BarrettDalhousie Human Immunology and Inflammation Group, Department of Microbiology and Immunology, Dalhousie University, Sir Charles Tupper Medical Building, Room 7-C2, 5850 College Street, PO Box 15000, Halifax, NS, B3H 4R2, Canada.
Jean S MarshallDalhousie Human Immunology and Inflammation Group, Department of Microbiology and Immunology, Dalhousie University, Sir Charles Tupper Medical Building, Room 7-C2, 5850 College Street, PO Box 15000, Halifax, NS, B3H 4R2, Canada. jean.marshall@dal.ca.
Nova Scotia Health Authority · CADalhousie University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histamine receptor 2 (H2R) blockade is commonly used in patients with gastric, duodenal ulcers or gastroesophageal reflux disease. Beyond the gastrointestinal tract, H2R is expressed by multiple immune cells, yet little is known about the immunomodulatory effects of such treatment. Clinical reports have associated H2R blockade with leukopenia, neutropenia, and myelosuppression, and has been shown to provide clinical benefit in certain cancer settings. To systematically assess effects of H2R blockade on key immune parameters, a single-center, single-arm clinical study was conducted in 29 healthy subjects. Subjects received daily high dose ranitidine for 6 weeks. Peripheral blood immunophenotyping and mediator analysis were performed at baseline, 3 and 6 weeks into treatment, and 12 weeks after treatment cessation. Ranitidine was well-tolerated, and no drug related adverse events were observed. Ranitidine had no effect on number of neutrophils, basophils or eosinophils. However, ranitidine decreased numbers of B cells and IL-2Rα (CD25) expressing T cells that remained lower even after treatment cessation. Reduced serum levels of IL-2 were also observed and remained low after treatment. These observations highlight a previously unrecognised immunomodulatory sustained impact of H2R blockade. Therefore, the immune impacts of H2R blockade may require greater consideration in the context of vaccination and immunotherapy.

Indexed as

AdultCD4 Lymphocyte CountFemaleHealthy VolunteersHistamine H2 AntagonistsHumansImmunomodulationInterleukin-2LeukocytesMaleMiddle AgedProspective StudiesRanitidineYoung AdultHistamine H2 AntagonistsInterleukin-2Ranitidine

Identifiers

PMID33931709
PMCPMC8087813
OpenAlexW3158819655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.